Journal of Neurology

, Volume 266, Issue 3, pp 775–776 | Cite as

Atypical parkinsonism with severely reduced striatal dopamine uptake associated with a 16p11.2 duplication syndrome

  • Benjamin Roeben
  • Dominik Blum
  • Heinz Gabriel
  • Matthis SynofzikEmail author
Letter to the Editors

Dear Sirs,

Copy number variants (CNVs) at the chromosome 16p11.2 are among the most frequent risk factors for neurodevelopmental and psychiatric conditions [1], such as autism spectrum disorder [2], schizophrenia [3] or intellectual impairment [4]. A link to parkinsonism has been discussed based on a single report of a child with an atypical combination of paroxysmal kinesiogenic dyskinesia (PKD) and parkinsonism carrying a 16p11.2 microdeletion [5]. Yet, confirmatory evidence from a second independent case with a 16p11.2 CNV as well as more direct evidence for nigro-striatal vulnerability is still missing. Moreover, it remains unclear whether parkinsonism might be associated only with 16p11.2 microdeletions or also with other 16p11.2 CNV types, as different 16p11.2 CNVs can be associated with different phenotypes [1]. We here show that parkinsonism and nigro-striatal vulnerability can be associated with a 16p11.2 duplication.

Case Report. A 69-year-old male with negative family...



MS was supported by the Else Kröner-Fresenius Stiftung.

Author Contributions

Collection and analysis of data: BR, DB, HG, MS. Drafting of the manuscript: BR, MS. Critical review of the manuscript: BR, DB, HG, MS.

Compliance with ethical standards

Conflicts of interest

None to declare.

Ethical standards

The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All individuals gave written informed consent prior to their inclusion in the present study.

Supplementary material

415_2019_9182_MOESM1_ESM.docx (28 kb)
Supplementary material 1 (DOCX 27 KB)


  1. 1.
    Martin-Brevet S et al (2018) Quantifying the effects of 16p11.2 copy number variants on brain structure: a multisite genetic-first study. Biol Psychiatry 84(4):253–264CrossRefGoogle Scholar
  2. 2.
    Weiss LA et al (2008) Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 358(7):667–675CrossRefGoogle Scholar
  3. 3.
    McCarthy SE et al (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 41(11):1223–1227CrossRefGoogle Scholar
  4. 4.
    Steinman KJ et al (2016) 16p11.2 deletion and duplication: characterizing neurologic phenotypes in a large clinically ascertained cohort. Am J Med Genet A 170(11):2943–2955CrossRefGoogle Scholar
  5. 5.
    Rana HQ et al (2013) Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med 15(2):146–149CrossRefGoogle Scholar
  6. 6.
    Barrett MJ et al (2013) Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis 36(3):575–580CrossRefGoogle Scholar
  7. 7.
    Gan-Or Z et al (2015) Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84(9):880–887CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Benjamin Roeben
    • 1
    • 2
  • Dominik Blum
    • 1
    • 3
  • Heinz Gabriel
    • 4
  • Matthis Synofzik
    • 1
    • 2
    Email author
  1. 1.Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research (HIH)University of TübingenTübingenGermany
  2. 2.German Center for Neurodegenerative Diseases (DZNE)TübingenGermany
  3. 3.Department of Nuclear Medicine and Clinical Molecular ImagingUniversity of TübingenTübingenGermany
  4. 4.CeGaT GmbH/Praxis für Humangenetik TübingenTübingenGermany

Personalised recommendations